My research focuses first on alterations of haemostasis in multiple myeloma (MM) patients and also in other haematological malignancies especially in case of thrombocytopenia. I am investigating hypercoagulable changes in MM (elevated FVIII, increased thrombin generation in presence of thrombomodulin…). Recently I started studies to better understand extracellular vesicles (EVs) implication in those alterations (notably EVs bearing tissue factor). I work on the implementation of some of those candidate biomarkers to guide the use of thromboprophylaxis for MM patients.
We also explore the impact of the different thromboprophylaxis approaches on coagulation phenotyping (pharmacokinetic-pharmacodynamic link).
Moreover, the fine characterization of subpopulations of EVs should enable to us to gain knowledge on the expression of EVs surface markers especially for endothelial markers (immunomodulatory drugs or CAR T cell setting) and markers that are targeted by immunotherapy (antitumoral treatment CD38, CD269).
